Profiel
Randall G.
Rupp served as Director-Cell Biology at Damon Biotech, Inc. He then worked at Regeneron Pharmaceuticals, Inc. for 17 years, where he held the position of Senior Vice President-Manufacturing Operations.
After leaving Regeneron, he worked as Vice President-Manufacturing & Development at Noveome Biotherapeutics, Inc. and as Vice President-Research & Development at BioHybrid Technologies, Inc. Rupp holds a doctorate degree from The University of Texas at Austin.
Eerdere bekende functies van Randall G. Rupp
| Bedrijven | Functie | Einde |
|---|---|---|
| REGENERON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 02-04-2008 |
| Damon Biotech, Inc. | Corporate Officer/Principal | - |
| BioHybrid Technologies, Inc. | Hoofd Techniek/Wetenschap/O&O | - |
Noveome Biotherapeutics, Inc.
 Noveome Biotherapeutics, Inc. BiotechnologyHealth Technology Noveome Biotherapeutics, Inc. develops novel biotherapeutic products that restore cell communication and system homeostasis. Its proprietary technology platform, derived from human placental cells, provides an exciting new approach to tissue regeneration and repair in a wide range of medical conditions and offers hope, especially in patients with maladies. The company was founded in 2001 by George L. Sing and William J. Golden and is headquartered in Pittsburgh, PA. | Corporate Officer/Principal | - |
Opleiding van Randall G. Rupp
| The University of Texas at Austin | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| REGENERON PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
| Damon Biotech, Inc. | Health Technology |
Noveome Biotherapeutics, Inc.
Noveome Biotherapeutics, Inc. BiotechnologyHealth Technology Noveome Biotherapeutics, Inc. develops novel biotherapeutic products that restore cell communication and system homeostasis. Its proprietary technology platform, derived from human placental cells, provides an exciting new approach to tissue regeneration and repair in a wide range of medical conditions and offers hope, especially in patients with maladies. The company was founded in 2001 by George L. Sing and William J. Golden and is headquartered in Pittsburgh, PA. | Health Technology |
| BioHybrid Technologies, Inc. |
